Indonesian Political, Business & Finance News

Airlangga Confident RI-China JV Will Boost Independence of Pharmaceutical Industry

| Source: Antara (Indonesian) Translated from Indonesian | Business
Airlangga Confident RI-China JV Will Boost Independence of Pharmaceutical Industry
Image: Antara (Indonesian)

Jakarta (ANTARA) - Coordinating Minister for Economic Affairs Airlangga Hartarto believes that a joint venture (JV) between the Indonesian and Chinese pharmaceutical industries can strengthen the self-reliance of the national drug industry, particularly in developing biopharmaceutical products to meet public health needs.

Airlangga made the remarks while attending the inauguration of PT Tempo CTTQ Biopharmaceutical Indonesia (TCBI), a company formed through cooperation between PT Tempo Scan Pacific Tbk and Chia Tai Tianqing Pharmaceutical Group Co., Ltd (CTTQ), a leading subsidiary of Chinese pharmaceutical firm Sino Biopharmaceutical Limited (SBP Group), held in Jakarta on Friday.

“This cooperation is expected to drive bio-based products, especially for diseases that are currently among the top killers, including heart disease, diabetes, liver disease and others,” said Airlangga.

According to him, developing the biopharmaceutical industry through this partnership is an important step towards increasing self-reliance in domestic drug production.

He noted that Indonesia remains dependent on imported pharmaceutical products, particularly innovative medicines at relatively high prices.

“And the hope is that with biopharmaceuticals we gain additional self-reliance in medicines that have so far depended on imports,” he said.

Airlangga said drug production through domestic facilities is expected to bring down prices, making medicines more affordable for the public, including through the national health insurance system.

“The medicines to be produced here include imported drugs that are relatively expensive compared to other countries, including Malaysia. So by producing them locally, prices are expected to come down and become accessible through the BPJS insurance system,” he said.

SBP Group is a China-based pharmaceutical company focused on research and development (R&D), with capabilities spanning research, manufacturing and the commercialisation of innovative drugs, biological products and quality branded medicines.

Through the formation of TCBI, Tempo Scan and CTTQ will develop a specialty pharmaceutical and innovative healthcare platform in Indonesia.

The company targets the phased launch of several innovative products over the coming years, including products that have already obtained approval as well as those still in the registration process.

Executive Chairman and Co-founder of Tempo Scan Group Handojo S Muljadi said the partnership is a strategic move to strengthen the company’s biotechnology and specialty pharmaceutical business.

“This joint venture is tangible proof that Indonesia is a long-term investment destination for foreign investors,” said Handojo.

The cooperation is also expected to strengthen the development of the national pharmaceutical industry’s capabilities, as well as reinforce Indonesia’s healthcare ecosystem.

More from 24 July 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/airlangga-confident-ri-china-jv-will-boost-independence-of-pharmaceutical-industry-1784879704)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5664041/airlangga-yakin-jv-industri-ri-china-pacu-kemandirian-industri-farmasi), translated from Indonesian
Print